
Catalent swallows VMIC Ltd
The biologics development and manufacturing facility taken over from Vaccine Manufacturing and Innovation Centre UK Ltd. is locaterd n to the south...

Four new autoantigens trigger multiple sclerosis
Despite considerable progress in the treatment of multiplesclerosis (MS), the disease still often leads to permanent neurological disability....

Novo Holdings co-leads €40m Qure.ai financing
Qure.ai said it will use the proceeds from the $40m financing round to intesify product development for critical care and community...

EMA delays Valneva vaccine approval
The CHMP’s action puts pressure on the French-Austrian vaccine developer, which wanted to market the vaccine from April on as the UK has already...

Sanofi and IGM Biosciences Inc. in $6.15bn deal
Under the agreement, IGM Biosciences Inc. (Mountain View) will discover IgM antibody agonists against three oncology targets and...

Bavarian Nordic bags $225m for licence to RSV vaccine
Under the terms of the agreement, Bavarian Nordic A/S (Copenhagen) will receive an upfront payment of US$12.5m and potential milestone payments of up...

Mimetas BV participating in €325m cancer funding
As part of a financing of the Dutch Naional Growth Fund the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) initiative has been granted...